{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:46:31Z","timestamp":1793213191753,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.metabol.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T04:16:58Z","timestamp":1511497018000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Biology and treatment of myeloma related bone disease"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.11.012_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/ehm.09.36","article-title":"Pathogenesis and management of myeloma bone disease","volume":"2","author":"Christoulas","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0010","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligandosteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcb.10613","article-title":"Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.metabol.2017.11.012_bb0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/14728220903025770","article-title":"Dickkopf-1: a suitable target for the management of myeloma bone disease","volume":"13","author":"Gavriatopoulou","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.metabol.2017.11.012_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2017.11.012_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/clinchem\/47.1.74","article-title":"Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity","volume":"47","author":"Janckila","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2017.11.012_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/bit.20939","article-title":"Differentiation of mesenchymal stem cells into osteoblasts on honeycomb collagen scaffolds","volume":"95","author":"George","year":"2006","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.metabol.2017.11.012_bb0045","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1210\/endo-119-4-1654","article-title":"Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption","volume":"119","author":"McSheehy","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2017.11.012_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/ortho\/25.2.101","article-title":"Bone remodelling","volume":"25","author":"Phill","year":"1998","journal-title":"Br J Orthod"},{"key":"10.1016\/j.metabol.2017.11.012_bb0055","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2017.11.012_bb0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2017.11.012_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2017.11.012_bb0070","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2017.11.012_bb0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1530\/eje.0.1390152","article-title":"Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis","volume":"139","author":"Hofbauer","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0080","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1359\/jbmr.080207","article-title":"Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction","volume":"23","author":"Kogianni","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0085","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.metabol.2017.11.012_bb0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.1998.8610","article-title":"Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone","volume":"246","author":"Tsukii","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2017.11.012_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2017.11.012_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2017.11.012_bb0105","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.metabol.2017.11.012_bb0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2017.11.012_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2017.11.012_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westendorf","year":"2004","journal-title":"Gene"},{"key":"10.1016\/j.metabol.2017.11.012_bb0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2017.11.012_bb0135","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.2489","article-title":"Suppression of bone formation by osteoclastic expression of semaphorin 4D","volume":"17","author":"Negishi-Koga","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2017.11.012_bb0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2017.11.012_bb0145","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.metabol.2017.11.012_bb0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.22030","article-title":"The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: a 13-year prospective study","volume":"86","author":"Diamond","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.metabol.2017.11.012_bb0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1999.01194.x","article-title":"Economic impact of using clodronate in the management of patients with multiple myeloma","volume":"104","author":"Bruce","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2141.1999.01193.x","article-title":"Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma","volume":"104","author":"Sati","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0190","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.metabol.2017.11.012_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","article-title":"Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells","volume":"100","author":"Mancino","year":"2001","journal-title":"J Surg Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/gut.2004.044370","article-title":"The RANKL\/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss","volume":"54","author":"Moschen","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2017.11.012_bb0205","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S8756-3282(01)00682-2","article-title":"Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis","volume":"30","author":"Romas","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.11.012_bb0210","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2017.11.012_bb0215","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0220","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0225","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappa B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0230","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappa B ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0240","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0245","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.metabol.2017.11.012_bb0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/eje.0.1450225","article-title":"Expression and secretion of activin A: possible physiological and clinical implications","volume":"145","author":"Luisi","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-385961-7.00013-5","article-title":"The regulation and functions of activin and follistatin in inflammation and immunity","volume":"85","author":"Hedger","year":"2011","journal-title":"Vitam Horm"},{"key":"10.1016\/j.metabol.2017.11.012_bb0260","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1096\/fj.07-8080com","article-title":"The activin A-follistatin system: potent regulator of human extracellular matrix mineralization","volume":"21","author":"Eijken","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2017.11.012_bb0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lfs.2007.04.011","article-title":"Changes in extracellular activin A: follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes","volume":"81","author":"Kawabata","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2017.11.012_bb0270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/bbrc.2000.2075","article-title":"Activin A is an essential cofactor for osteoclast induction","volume":"268","author":"Fuller","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2017.11.012_bb0275","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0280","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","article-title":"Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma","volume":"64","author":"Abildgaard","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00163574","article-title":"Myeloma affects both the growth and function of human osteoblast-like cells","volume":"10","author":"Evans","year":"1992","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.metabol.2017.11.012_bb0290","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0295","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.metabol.2017.11.012_bb0300","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.11.012_bb0305","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0310","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell"},{"key":"10.1016\/j.metabol.2017.11.012_bb0315","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signalling in osteoblasts regulates expression of the receptor activator of NF kappaB ligand and inhibits osteoclastogenesis in vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.metabol.2017.11.012_bb0320","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.metabol.2017.11.012_bb0325","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.metabol.2017.11.012_bb0330","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Delgado-Calle","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.metabol.2017.11.012_bb0335","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMct1004903","article-title":"Bisphosphonates for osteoporosis","volume":"363","author":"Favus","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.11.012_bb0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.metabol.2017.11.012_bb0345","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"40","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.11.012_bb0350","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0355","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0360","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.metabol.2017.11.012_bb0365","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study","volume":"2","author":"Daragon","year":"1993","journal-title":"Eur J Med"},{"key":"10.1016\/j.metabol.2017.11.012_bb0370","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0375","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.metabol.2017.11.012_bb0380","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.metabol.2017.11.012_bb0385","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.11.012_bb0390","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0395","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0400","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0405","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.metabol.2017.11.012_bb0410","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0415","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0420","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0425","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.metabol.2017.11.012_bb0430","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.metabol.2017.11.012_bb0435","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0440","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2016.04.088","article-title":"Adverse cardiovascular effects of nitrogen-containing bisphosphonates in patients with osteoporosis: A nationwide population-based retrospective study","volume":"215","author":"Wang","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0445","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00198-014-3020-y","article-title":"Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study","volume":"26","author":"Herrera","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.11.012_bb0450","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.11.012_bb0455","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1073\/pnas.1704460114","article-title":"Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance","volume":"114","author":"Lloyd","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2017.11.012_bb0460","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomized controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0465","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.metabol.2017.11.012_bb0470","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0475","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.metabol.2017.11.012_bb0480","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK Study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0485","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0490","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0495","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1359-6349(06)70202-6","article-title":"Denosumab is a selective inhibitor of human receptor activator of NF-KB ligand that blocks osteoclast formation in vitro and in vivo","volume":"4","author":"Elliott","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.metabol.2017.11.012_bb0500","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0505","first-page":"331","article-title":"Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients","volume":"7","author":"Yee","year":"2012","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.metabol.2017.11.012_bb0510","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0515","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1349-7006.2008.00803.x","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.metabol.2017.11.012_bb0520","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0525","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0530","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0535","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","article-title":"Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial","volume":"6","author":"Raje","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.metabol.2017.11.012_bb0540","series-title":"Presented at 16th International Myeloma Workshop, March 1-4","article-title":"An international, randomized, double blind trial comparing denosumab with zoledronic acid (ZA) for the treatment of bone disease in patients (Pts) with newly diagnosed multiple myeloma. OP-046","author":"Raje","year":"2017"},{"issue":"s1","key":"10.1016\/j.metabol.2017.11.012_bb0545","first-page":"318","article-title":"Comparison of denosumab with zoledronic acid for the treatment of bone disease in patients with newly diagnosed multiple myeloma; an international, randomized, double blind trial","volume":"102","author":"Terpos","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.metabol.2017.11.012_bb0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/0-387-24180-9_12","article-title":"The innate functions of dendritic cells in peripheral lymphoid tissues","volume":"560","author":"Steinman","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0555","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0560","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1073\/pnas.0711263105","article-title":"A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity","volume":"105","author":"Pearsall","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2017.11.012_bb0565","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bone.2009.09.018","article-title":"Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis)","volume":"46","author":"Fajardo","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.11.012_bb0570","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","article-title":"A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via dual anabolic-antiresorptive effect in Cynomolgus monkeys","volume":"46","author":"Lotinum","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.11.012_bb0575","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0580","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0585","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","article-title":"Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy","volume":"27","author":"Scullen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.metabol.2017.11.012_bb0590","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0595","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2017.11.012_bb0600","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.11.012_bb0605","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0610","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14728220902841961","article-title":"Wnt signaling as a therapeutic target for bone diseases","volume":"13","author":"Hoeppner","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.metabol.2017.11.012_bb0615","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrrheum.2011.130","article-title":"New targets for intervention in the treatment of postmenopausal osteoporosis","volume":"7","author":"Lewiecki","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.metabol.2017.11.012_bb0620","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517303244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517303244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:15:52Z","timestamp":1758428152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517303244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":124,"alternative-id":["S0026049517303244"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.11.012","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biology and treatment of myeloma related bone disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}